Lakefront Biotherapeutics (GLPGF) Net Margin (2014 - 2026)
Lakefront Biotherapeutics' (GLPGF) quarterly Net Margin came in at 356.24% in Q2 2026, down 59447.0% year-over-year from N/an in Q2 2025, and down 259.32% quarter-over-quarter from 223.61% in Q1 2026.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Net Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Net Margin for 13 consecutive years, with 356.24% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Margin fell 59447.0% year-over-year to 356.24% in Q2 2026; TTM through Jun 2026 was 32377.09%, a 1111954.0% increase from a year earlier, with the FY2025 full-year figure at 28850.04%, up 197456.0% from the prior year.
- Net Margin was 356.24% for Q2 2026 at Lakefront Biotherapeutics, down from 223.61% in the prior quarter.
- Over five years, Net Margin peaked at 197421.93% in Q4 2024 and troughed at 700.76% in Q3 2025.
- A 5-year average of 15051.75% and a median of 4.4% in 2022 frame the typical range for Net Margin.
- Across the five-year window, Net Margin soared 15850269 bps in 2024 and sank 16174949 bps in 2025, its largest moves.
- Over 5 years, Net Margin stood at 135.44% in 2022, then jumped by 28835 bps to 38919.25% in 2023, then surged by 407 bps to 197421.93% in 2024, then slumped by 82 bps to 35672.45% in 2025, then sank by 101 bps to 356.24% in 2026.
- The last three Net Margin figures came in at 356.24% (Q2 2026), 223.61% (Q1 2026), and 35672.45% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -20,152.98% |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -356.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -356.24% |
| Mar 31, 2026 | 223.61% |
| Dec 31, 2025 | 35,672.45% |
| Sep 30, 2025 | -700.76% |
| Jun 30, 2025 | 238.22% |
| Mar 31, 2025 | -204.60% |
| Dec 31, 2024 | 197,421.93% |
| Sep 30, 2024 | -59.52% |
| Jun 30, 2024 | -211.70% |
| Mar 31, 2024 | 144.51% |
| Dec 31, 2023 | 38,919.25% |
| Sep 30, 2023 | -53.02% |
| Jun 30, 2023 | 0.97% |
| Mar 31, 2023 | 39.62% |
| Dec 31, 2022 | -135.44% |
| Sep 30, 2022 | 15.83% |
| Jun 30, 2022 | -13.82% |
| Mar 31, 2022 | -9.76% |
| Dec 31, 2021 | 65.82% |
| Sep 30, 2021 | -48.38% |